FIGURE 7.

Rofecoxib treatment alleviated the disease progression of SOD1^G93A mice. SOD1^G93A mice were orally administered rofecoxib (50 mg/kg/day) until dead or the end stage of ALS. (A) Body weight was monitored over the entire lifespans of SOD1^G93A mice treated or not treated with rofecoxib (50 mg/kg/day). (B) The probability of ALS onset was determined on the basis of body weight. (C) The step size and stride width were further calculated and statistically analyzed with GraphPad Prism 5. (D) The survival percentages of the different groups of mice were calculated. The data represent the means ± SEs from independent experiments. For body weight, **p < 0.01; ***p < 0.001, compared with vehicle-treated SOD1^G93A mice. For the step size and stride width, ***p < 0.001, compared with non-transgenic mice and ^#p < 0.05, compared with vehicle-treated SOD1^G93A mice.